Matches in SemOpenAlex for { <https://semopenalex.org/work/W4224056104> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W4224056104 endingPage "174" @default.
- W4224056104 startingPage "172" @default.
- W4224056104 abstract "The rates of suspected allergic reactions to the first dose of the coronavirus disease 2019 (COVID-19) mRNA vaccines have been reported to be as high as 2%, with an anaphylaxis incidence up to 2.5 per 10,000 individuals. Anaphylaxis in response to the first dose may be considered a contraindication to administration of the second dose, even though the second dose is necessary for optimal protection against severe disease. Many individuals with anaphylactic reactions to the first dose still want to receive a second dose. However, there are few published data to support the safety of administration of a second dose in this population.The primary objective of this study was to determine the percentage of patients tolerating a second COVID-19 mRNA vaccine dose after an immediate reaction to the first dose.This was a retrospective chart review of 47 patients at a Canadian hospital who had immediate, suspected allergic reactions following their first COVID-19 mRNA vaccine dose and received a second dose within our allergy clinic.Of 47 patients, 46 tolerated the second dose; 43% of patients developed mild, transient symptoms. There were no patients who developed anaphylaxis or needed epinephrine after the second dose.Our case series adds to current evidence that administration of a second COVID-19 mRNA vaccine dose has a good safety profile in patients with a history of immediate reactions after the first dose, including those with a history of anaphylaxis in response to the first dose." @default.
- W4224056104 created "2022-04-19" @default.
- W4224056104 creator A5015488905 @default.
- W4224056104 creator A5022549243 @default.
- W4224056104 creator A5034638128 @default.
- W4224056104 creator A5054011595 @default.
- W4224056104 date "2022-08-01" @default.
- W4224056104 modified "2023-09-30" @default.
- W4224056104 title "Second-dose mRNA COVID-19 vaccine safety in patients with immediate reactions after the first dose: A case series" @default.
- W4224056104 cites W3128551684 @default.
- W4224056104 cites W3134831990 @default.
- W4224056104 cites W3176353132 @default.
- W4224056104 cites W3186013111 @default.
- W4224056104 doi "https://doi.org/10.1016/j.jacig.2022.03.003" @default.
- W4224056104 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36203478" @default.
- W4224056104 hasPublicationYear "2022" @default.
- W4224056104 type Work @default.
- W4224056104 citedByCount "1" @default.
- W4224056104 countsByYear W42240561042023 @default.
- W4224056104 crossrefType "journal-article" @default.
- W4224056104 hasAuthorship W4224056104A5015488905 @default.
- W4224056104 hasAuthorship W4224056104A5022549243 @default.
- W4224056104 hasAuthorship W4224056104A5034638128 @default.
- W4224056104 hasAuthorship W4224056104A5054011595 @default.
- W4224056104 hasBestOaLocation W42240561041 @default.
- W4224056104 hasConcept C126322002 @default.
- W4224056104 hasConcept C142724271 @default.
- W4224056104 hasConcept C187212893 @default.
- W4224056104 hasConcept C203014093 @default.
- W4224056104 hasConcept C204787440 @default.
- W4224056104 hasConcept C207480886 @default.
- W4224056104 hasConcept C2775933838 @default.
- W4224056104 hasConcept C2776494729 @default.
- W4224056104 hasConcept C27924281 @default.
- W4224056104 hasConcept C2908647359 @default.
- W4224056104 hasConcept C71924100 @default.
- W4224056104 hasConcept C99454951 @default.
- W4224056104 hasConceptScore W4224056104C126322002 @default.
- W4224056104 hasConceptScore W4224056104C142724271 @default.
- W4224056104 hasConceptScore W4224056104C187212893 @default.
- W4224056104 hasConceptScore W4224056104C203014093 @default.
- W4224056104 hasConceptScore W4224056104C204787440 @default.
- W4224056104 hasConceptScore W4224056104C207480886 @default.
- W4224056104 hasConceptScore W4224056104C2775933838 @default.
- W4224056104 hasConceptScore W4224056104C2776494729 @default.
- W4224056104 hasConceptScore W4224056104C27924281 @default.
- W4224056104 hasConceptScore W4224056104C2908647359 @default.
- W4224056104 hasConceptScore W4224056104C71924100 @default.
- W4224056104 hasConceptScore W4224056104C99454951 @default.
- W4224056104 hasIssue "3" @default.
- W4224056104 hasLocation W42240561041 @default.
- W4224056104 hasLocation W42240561042 @default.
- W4224056104 hasLocation W42240561043 @default.
- W4224056104 hasOpenAccess W4224056104 @default.
- W4224056104 hasPrimaryLocation W42240561041 @default.
- W4224056104 hasRelatedWork W2324126613 @default.
- W4224056104 hasRelatedWork W2355568291 @default.
- W4224056104 hasRelatedWork W2381280891 @default.
- W4224056104 hasRelatedWork W2391620383 @default.
- W4224056104 hasRelatedWork W2416748870 @default.
- W4224056104 hasRelatedWork W2432334971 @default.
- W4224056104 hasRelatedWork W2782315116 @default.
- W4224056104 hasRelatedWork W3093530561 @default.
- W4224056104 hasRelatedWork W4224056104 @default.
- W4224056104 hasRelatedWork W4381716239 @default.
- W4224056104 hasVolume "1" @default.
- W4224056104 isParatext "false" @default.
- W4224056104 isRetracted "false" @default.
- W4224056104 workType "article" @default.